Dr. Shi Ke’s research career started in M.D. Anderson Cancer Center after 7 years clinical practice as a general surgeon. His molecular imaging research project started in 2002. All of target-specific agents he developed are dual-labeled for imaging and therapy. His researches focus on the combination of imaging, chemistry and biology to address the disease diagnosis and treatment. His facility has capability perform bioluminescence, optical, nuclear, X-ray, SPECT, PET and CT imagings. He filed 5 patent disclosures since 2008 and more than 40 publications. He is the member of the Scientific Advisory Board for Carestream Molecular Imaging. Dr. Shi Ke’s research career started in M.D. Anderson Cancer Center after 7 years clinical practice as a general surgeon. His molecular imaging research project started in 2002. All of target-specific agents he developed are dual-labeled for imaging and therapy. His researches focus on the combination of imaging, chemistry and biology to address the disease diagnosis and treatment. His facility has capability perform bioluminescence, optical, nuclear, X-ray, SPECT, PET and CT imagings. He filed 5 patent disclosures since 2008 and more than 40 publications. He is the member of the Scientific Advisory Board for Carestream Molecular Imaging.

Gastroenterology